Evidence map›Paper›PMID 30647128›Full record

ArticleThe Journal of biological chemistry2019

Bile acid analogues are activators of pyrin inflammasome.

Irina Alimov, Suchithra Menon, Nadire Cochran, Rob Maher, Qiong Wang, John Alford, John B Concannon, Zinger Yang, Edmund Harrington, Luis Llamas and 7 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Inducing Pyroptosis Via the Pyrin Inflammasome.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 2 countries.

Irina AlimovFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Suchithra MenonFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Nadire CochranFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Rob MaherFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Qiong WangFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
John AlfordFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
John B ConcannonFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Zinger YangFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.ORCID 0000-0001-8543-4841
Edmund HarringtonFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Luis LlamasFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Alicia LindemanFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Gregory HoffmanFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Tim Schuhmannthe Novartis Institute for Biomedical Research, Novartis Pharma AG, Forum 1 Novartis Campus, 4056 Basel, Switzerland.
Carsten RussFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
John Reece-HoyesFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and.
Stephen M CanhamFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and steve.canham@novartis.com.
Xinming CaiFrom the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139 and xinming.cai@sanofi.com.
Novartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bile acids are critical metabolites in the gastrointestinal tract and contribute to maintaining intestinal immune homeostasis through cross-talk with the gut microbiota. The conversion of bile acids by the gut microbiome is now recognized as a factor affecting both host metabolism and immune responses, but its physiological roles remain unclear. We conducted a screen for microbiome metabolites that would function as inflammasome activators and herein report the identification of 12-oxo-lithocholic acid (BAA485), a potential microbiome-derived bile acid metabolite. We demonstrate that the more potent analogue 11-oxo-12

Indexed as

Immunity, MucosalBile Acids and SaltsEpithelial CellsGastrointestinal MicrobiomeHumansInflammasomesIntestinal MucosaMyeloid CellsPyrinTHP-1 CellsBile Acids and SaltsInflammasomesMEFV protein, humanPyrinautoimmune diseasebile acidbiotransformationCRISPR/CasCRISPR screenfamilial Mediterranean fevergut homeostasisimmune responseinflammasomemicrobiomemicrobiotamucosal immunologypyrin

Identifiers

PMID30647128
PMCPMC6416436
OpenAlexW2910666367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.